IQVIA Holdings Inc (IQV)vsMyriad Genetics Inc (MYGN)
IQV
IQVIA Holdings Inc
$228.20
-2.21%
HEALTHCARE · Cap: $38.68B
MYGN
Myriad Genetics Inc
$3.17
+4.97%
HEALTHCARE · Cap: $514.74M
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 2949% more annual revenue ($16.98B vs $557.00M). IQV leads profitability with a 8.1% profit margin vs -41.3%. IQV appears more attractively valued with a PEG of 0.98. IQV earns a higher WallStSmart Score of 55/100 (C).
IQV
Buy55
out of 100
Grade: C
MYGN
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.9%
Fair Value
$201.09
Current Price
$228.20
$27.11 discount
Margin of Safety
+89.5%
Fair Value
$46.12
Current Price
$3.17
$42.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -118.5% — below average capital efficiency
Revenue declined 20.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.58 is elevated, increasing financial risk.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
IQV profiles as a value stock while MYGN is a turnaround play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
IQV is growing revenue faster at 8.7% — sustainability is the question.
IQV generates stronger free cash flow (491M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 44/100). MYGN offers better value entry with a 89.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?